Company: SUPN
Filing Date: 2025-08-04
Form Type: 8-K
Source: 0001356576-25-000050
Chunk: 0

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-04
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

of Certain Officers.

(e) Modification of Compensatory Arrangements with Executive Officers

On May 30, 2025, the Compensation Committee (“ Committee”) of Supernus Pharmaceuticals, Inc. (“ Supernus” or the “ Company”) recommended, and the Board of Directors (the “ Board”) approved, appointing Frank Mottola, previously the Company’s Senior Vice President, Quality, GMP Operations and IT, as the Company’s Chief Technical Operations Officer, effective June 16, 2025, and the modifications of the compensation of Frank Mottola, as follows:

The annual base salary of Frank Mottola was increased from $392,500 to $412,500. Mr. Mottola’s bonus target for 2025 was increased from 35% to 40% of his base salary. All other terms and conditions of the Company’s compensatory arrangements with Mr. Mottola remain unchanged.

Item 9.01 Financial Statements and Exhibits.